Phase I clinical trial of chemoimmunotherapy in combination with radiotherapy in stage IIIB cervical cancer patients

International Journal of Gynecological Cancer

Volumn 13, Issue 5, 2003, Pages 652-656

  Wilailak, Sarikapan ^a   Dangprasert, S ^a   Srisupundit, S ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Cervical cancer; Chemoimmunotherapy; Radiotherapy; Stage IIIB

Indexed keywords

ALPHA2A INTERFERON; CISPLATIN; FLUOROURACIL; IRIDIUM 192; ISOTRETINOIN;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; ASTHENIA; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEILITIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE CALCULATION; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; HYDRONEPHROSIS; HYDROURETER; HYPERTRIGLYCERIDEMIA; LEUKOPENIA; LIVER TOXICITY; MOUTH INFLAMMATION; MUCOSA INFLAMMATION; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TUMOR VOLUME; UTERINE CERVIX CANCER;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; ISOTRETINOIN; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 1242291828     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2003.13300.x     Document Type: Article

References (30)

1. Stehman FB, Perez CA, Kurman RJ, Thigpen JT. Uterine cervix. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology. Philadelphia: Lippincott Williams & Wilkins, 2000:841-918.
2. Fagundes H, Perez CA, Grigsby PW, Lockett MA. Distant metastases after irradiation alone in carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1992;24:197-204.
3. Lowrey GC, Mendenhall WM, Million RR. Stage IB or IIA-B carcinoma of the intact uterine cervix treated with irradiation: A multivariated analysis. Int J Radiat Oncol Biol Phys 1992;24:205-10.
4. Lanciano RM, Pajak TF, Martz K, Hanks GE. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: A pattern-of-care study. Int J Radiat Oncol Biol Phys 1993;25:391-7.
5. Benedet JL, Odicino F, Maisonnewe P, et al. Carcinoma of the cervix uteri. J Epidemiol Biostat 2001;6:5-44.
6. Omura GA. Chemotherapy for cervix cancer. Semin Oncol 1994;21:54-62.
7. Alberts DS, Garcia D, Mason-Liddil N. Cisplatin in advanced cancer of the cervix: an update. Semin Oncol 1991;18:S11-24.
8. Kaern J, Trope C, Sundfoer K, Kristensen GB. Cisplatin/ 5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up. Gynecol Oncol 1996;60:387-92.
9. Um SJ, Kim EJ, Hwang ES, Kim SJ, Namkoong SE, Park JS. Antiproliferative effects of retinoic acid/interferon in cervical carcinoma cell lines: cooperative growth suppression of IRF-1 and p53. Int J Cancer 2000;85:416-23.
10. Vannuchi S, Percario ZA, Chiantore MV et al. Interferon-β induces S phase slowing via up-regulated expression of PML in squamous carcinoma cells. Oncogene 2000;19:5041-53.
11. Lippman SM, Lotan R, Schleuniger U. Retinoid-interferon therapy of solid tumors. Int J Cancer 1997;70:481-3.
12. Lancillotti F, Giandomenico V, Aftabris E, Fiorucci G, Romeo G, Rossi GB. Interferon α-2a and retinoic acid combined treatment affects proliferation and gene expression of human cervical carcinoma cells. Cancer Res 1995;55:3158-64.
13. Linder DJ, Kalvakolanu DV, Bordeu EC. A combination of retinoic acid and IFN-β inhibits the in vitro and in vivo growth of a variety of tumors. J Interferon Cytokine Res 1995;15(Suppl):S217.
14. Park TK, Lee JP, Kim SM, Choi SM, Kudelka AP, Interferon α-2a, 13-cis-retinoic acid and radiotherapy for locally advanced carcinoma of the cervix: a pilot study. Eur J Gynaecol Oncol 1998;19:35-8.
15. Kavanagh JJ, Lippman SM, Paredes-Espinoza M. The combination of 13-cis-retinoic acid and interferon α-2a with radiation therapy in squamous cell carcinoma of the cervix. Int J Gynecol Cancer 1996;6:439-44.
16. Lippman SM, Kavanagh JJ, Paredes-Espinoza M et al. 13-cis retinoic acid plus interferon alpha 2a in locally advanced squamous cell carcinoma of the cervix. J Natl Cancer Inst 1993;85:499-500.
17. Lippman SM, Kavanagh JJ, Paredez-Espinoza M, et al. 13-cis retinoic acid plus interferon-alpha 2a: highly active systemic therapy for squamous cell carcinoma of the cervix. Int J Gynecol Cancer 1996;6:439-44.
18. Veerasaru V, Sritongchai C, Tepmongkol P, Senapad S. Randomized trial radiotherapy with and without concomitant 13-cis-retinoic acid plus interferon-alpha for locally advanced cervical cancer: A preliminary report. J Med Assoc Thai 1996;79:439-47.
19. Carmichael J, Ferguson RJ, Wolf CR, Balkwill FR, Smyth JF. Augmentation of cytotoxicity of chemotherapy by human α-interferon in human non-small cell lung cancer xenografts. Cancer Res 1986;46:4916-20.
20. Vokes EE. The promise of biochemical modulation in combined modality therapy. Semin Oncol 1994;21(Suppl 14):29-33.
21. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990;50:3473-86.
22. Fleming GF, O'Brien SM, Hoffman PC et al. Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin. Cancer Chemother Pharmacol 1997;39:227-32.
23. Tirney JF, Stewart LA. Neoadjuvant chemotherapy followed by radiotherapy for locally advanced cervix cancer: a meta-analysis using individual patient data from randomized controlled trials (RCTs). Proc ASCO 2002;21:207a.
24. Ajani JA, Welch SR, Raber MN et al. Comprehensive criteria for assessing therapy induced toxicity. Cancer Invest 1990;8:147-59.
25. Chang AY, Keng PC. Potentiation of radiation cytotoxicity by recombinant interferons, a phenomenon associated with increased blockage at the G2-M phase of the cell cycle. Cancer Res 1987;47:4338-41.
26. Rutz HP, Little JB. Modification of radiosensitivity and recovery from X-ray damage in vitro by retinoic acid. Int J Radiat Oncol Biol Phys 1989;16:1285-8.
27. Ryu S, Stein JP, Chung CT, Lee YJ, Kim JH. Enhanced apoptosis and radiosensitization by combined 13-cis-retinoic acid and interferon-α 2a; Role of RAR-β gene. Int J Radiat Oncol Biol Phys 2001;51:785-90.
28. Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.
29. Morris M, Eifel PJ, Lu J et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high risk cervical cancer. N Engl J Med 1999;340:1137-43.
30. Miglietta L, Bruzzone M, Ghione G et al. Chemotherapy with cisplatin and 5-fluorouracil chronomodulated infusion in locally advanced or metastatic/recurrent carcinoma of the cervix. Tumori 2002;88:204-8.